SCHEMBL31546321

SCHEMBL31546321

COc1ccc(-c2noc(=O)[nH]2)nc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.51
TNKS O95271 1/20 0.43
CBFB Q13951 1/20 0.42
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
PLA2G2A P14555 9/20 0.40
KMO O15229 1/20 0.40
PLA2G10 O15496 1/20 0.38
PLA2G1B P04054 1/20 0.38
PLA2G5 P39877 1/20 0.38
SCD O00767 1/20 0.37
SCD5 Q86SK9 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36
RARB P10826 1/20 0.36
CDC7 O00311 1/20 0.36
PLK4 O00444 1/20 0.36
AURKA O14965 1/20 0.36
MAPK13 O15264 1/20 0.36
DAPK3 O43293 1/20 0.36
DYRK3 O43781 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25435029 1.00 ALDH1A1 (0.51) ALDH1A1TNKSCBFBCYP4F2CYP4A11
SCHEMBL16285376 0.80 CCR1 (0.48) ALDH1A1PLA2G2AKMORARB
SCHEMBL25436249 0.80 ALDH1A1 (0.48) ALDH1A1PLA2G2AKMOPLA2G10PLA2G1B
SCHEMBL25432292 0.78 ALDH1A1 (0.69) ALDH1A1TNKSPLA2G2APLA2G10PLA2G1B
SCHEMBL25433544 0.77 ALDH1A1 (0.42) ALDH1A1PLA2G2AKMOPLA2G10PLA2G1B
SCHEMBL16285371 0.76 ALDH1A1 (0.48) ALDH1A1PLA2G2AKMOPLA2G10PLA2G1B
SCHEMBL7539758 0.73 ALDH1A1 (0.41) ALDH1A1CYP4F2CYP4A11PLA2G2AKMO
SCHEMBL3147993 0.72 CA12 (0.50) ALDH1A1TNKSCBFBRXFP1CLK4
SCHEMBL30335253 0.72 CA12 (0.50) ALDH1A1TNKSCBFBRXFP1CLK4
SCHEMBL25432943 0.71 ALDH1A1 (0.46) ALDH1A1PLA2G2AKMOPIM1PIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 ALDH1A1 4471/4885TNKS 1836/4885CBFB 238/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 ALDH1A1 4471/4885TNKS 1836/4885CBFB 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.